PMC:7795856 / 4274-4432 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7795856","sourcedb":"PMC","sourceid":"7795856","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7795856","text":" to an improved safety profile of immune checkpoint inhibitors [17]. Beyond that, emerging indications such as cystic fibrosis [18], multiple sclerosis [19], ","tracks":[{"project":"LitCovid-PubTator","denotations":[{"id":"141","span":{"begin":111,"end":126},"obj":"Disease"},{"id":"142","span":{"begin":133,"end":151},"obj":"Disease"}],"attributes":[{"id":"A141","pred":"tao:has_database_id","subj":"141","obj":"MESH:D003550"},{"id":"A142","pred":"tao:has_database_id","subj":"142","obj":"MESH:D009103"},{"subj":"141","pred":"source","obj":"LitCovid-PubTator"},{"subj":"142","pred":"source","obj":"LitCovid-PubTator"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-PubTator","color":"#93ecea","default":true}]}]}}